School of Medicine

Wayne State University School of Medicine

Research

We have the following ongoing clinical trials:

(If you're interested in participation or have any questions, please contact our Research Office at 313-745-9537.)

  • ATHENA-1 : A Randomized, Multicenter Study of Ambrisentan and Sildenafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to Sildenafil 
    Principal Investigator: Ghulam Saydain, M.D.
     
  • COMPASS-2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Prospective, Event Driven Phase IV Study.
    Principal Investigator
    : Ghulam Saydain, M.D.
  • REVEAL Registry:Registry to Evaluate Early And Long-Term PAH Disease Management. 
    Principal Investigator: Ghulam Saydain, M.D.
     
  • PAH QuERI: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative. 
    Principal Investigator: Ghulam Saydain, M.D.
     
  • SERAPHIN: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Event-Driven, Phase III Study to Assess the Effects of ACT-064992 on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension.
    Principal Investigator: Ghulam Saydain, M.D.
     

We have also successfully completed the following Clinical Trials in the past:

  • PHIRST-2: Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension.
    Principal Investigator: Ghulam Saydain, M.D./ Kamal Mubarak, M.D.
     
  • ARIES-3: Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension.
    Principal Investigator: Ghulam Saydain, M.D./ Kamal Mubarak, M.D.
     
  • STRIDE-III: Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension. 
    Principal Investigator: Kamal Mubarak, M.D.
     
  • ASSET-1 & ASSET-2: Randomized, Placebo-controlled, Double-blind, Multi-center, Parallel Group Study To Assess the Efficacy, Safety and Tolerability of Bosentan in Patients with Symptomatic Pulmonary Arterial Hypertension Associated with Sickle Cell Disease.
    Principal Investigator: Kamal Mubarak, M.D.
     
  • ASSET-3: Long-Term, Open-Label, Multi-center, Extension Study of Bosentan in Patients with Pulmonary Hypertension Associated with Sickle Cell Disease Completing a Double-blind ASSET study.
    Principal Investigator: Kamal Mubarak, M.D.
     
  • PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension.
    Principal Investigator: Kamal Mubarak, M.D.